SALT LAKE CITY, Jul 13, 2006 (BUSINESS WIRE) -- Schiff Nutrition International, Inc. (formerly Weider Nutrition International, Inc.) (WNI today announced results for the fiscal 2006 fourth quarter and year ended May 31, 2006.
Schiff Nutrition's net sales were $45.3 million for the three months ended May 31, 2006, compared to $39.9 million for the same period in fiscal 2005. For the fiscal 2006 fourth quarter, Schiff Nutrition reported net income of $6.2 million, or $0.23 per diluted share. This compares to a net loss of ($1.8) million, or ($0.07) per share, which included an after-tax loss from discontinued operations of ($5.7) million for the same period a year ago.
For fiscal 2006, Schiff Nutrition's net sales were $178.4 million, compared to fiscal 2005 net sales of $173.1 million. For fiscal 2006, Schiff Nutrition reported net income of $15.8 million, or $0.59 per diluted share, compared to net income of $6.6 million, or $0.25 per diluted share, for fiscal 2005. Fiscal 2006 financial results were favorably impacted from reimbursement of approximately $2.7 million in import related costs, recognition of $1.6 million in foreign currency gain related to liquidation of certain foreign entities subsequent to the Weider and Haleko business divestitures, and an approximate overall 13 percent effective tax rate. Net income for fiscal 2006 and 2005 included after-tax losses from discontinued operations of approximately ($127,000) and ($5.5) million, respectively.
Bruce Wood, President and Chief Executive Officer, stated, "Our fourth quarter performance was encouraging. The 13.3 percent net sales increase was driven by a 19.7 percent increase in our branded sales which, coupled with a meaningful improvement in our gross margin, contributed to the significant increase in operating earnings."
Wood continued, "We were pleased with the continued marketplace acceptance of our new Move Free(R) Advanced Formula, which responded positively to the significant increase in marketing support during the quarter. We plan to continue the higher level of marketing support behind Move Free Advanced in fiscal 2007, in recognition of the overall increased level of competitive activity we are observing in the joint care category. We remain confident our strategic focus on profitable branded growth will benefit fiscal 2007 and beyond."
About Schiff Nutrition
Schiff Nutrition International, Inc. (formerly Weider Nutrition International, Inc.) develops, manufactures, markets and distributes branded and private label vitamins, nutritional supplements and nutrition bars in the United States and throughout the world. To learn more about Schiff, please visit the web site www.schiffnutrition.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended, that are based on management's beliefs and assumptions, current expectations, estimates, and projections. These statements are subject to risks and uncertainties, certain of which are beyond the company's ability to control or predict, and, therefore, actual results may differ materially. Schiff Nutrition disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.
Important factors that may cause these forward-looking statements to be false include, but are not limited to: the inability to successfully launch Move Free Advanced, the level of customer and consumer acceptance of Move Free Advanced, the inability to successfully implement marketing and spending programs behind our Move Free brand and other new branded products, the impact of raw material pricing, availability and quality (particularly relating to joint care products and ingredients from suppliers outside the United States), the mix between branded and private label products and our ability to grow branded sales, the inability to achieve cost savings and operational efficiencies, the inability to increase operating margins and increase revenues, dependence on individual products, dependence on individual customers, the impact of competitive products and pricing (including private label), market and industry conditions (including pricing, demand for products and level of trade inventories), the impact of clinical studies regarding nutritional supplements, particularly relating to the joint care category, the success of product development, the inability to obtain customer acceptance of new product introductions, changes in laws and regulations, litigation and government regulatory action in the United States and internationally, the inability or increased cost to obtain product liability and general insurance, uncertainty of market acceptance of new products, adverse publicity regarding the consumption of nutritional supplements, the inability to find strategic acquisitions or the inability to successfully consummate or integrate an acquisition, changes in accounting standards, and other factors indicated from time to time in the company's SEC reports, copies of which are available upon request from the company's investor relations department or may be obtained at the SEC's web site ( www.sec.gov).